During the last session, Evofem Biosciences, Inc. (NASDAQ:EVFM)’s traded shares were 3,275,090, with the beta value of the company hitting -0.26. At the end of the trading day, the stock’s price was $1.74, reflecting an intraday loss of -4.4% or -$0.08. The 52-week high for the EVFM share is $6.87, that puts it down -294.83% from that peak though still a striking +5.17% gain since the share price plummeted to a 52-week low of $1.65. The company’s market capitalization is $174.47 Million, and the average intraday trading volume over the past 10 days was 5.66 Million shares, and the average trade volume was 4.87 Million shares over the past three months.
Evofem Biosciences, Inc. (EVFM) received a consensus recommendation of Overweight from analysts. That translates to a mean rating of 2. EVFM has a Sell rating from none of the analyst(s) out of 4 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 3 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.49.
Evofem Biosciences, Inc. (NASDAQ:EVFM): Trading Information
Evofem Biosciences, Inc. (EVFM) registered a -4.4% downside in the last session and has traded in the green over the past 5 sessions. The stock spiked 14.07% in intraday trading to $2.025 this Thursday, Apr 01, hitting a weekly high. The stock’s 5-day price performance is 0.58%, and it has moved by -23.68% in 30 days. Based on these gigs, the overall price performance for the year is -27.8%. The short interest in Evofem Biosciences, Inc. (NASDAQ:EVFM) is 8.93 Million shares and it means that shorts have 1.83 day(s) to cover.
The consensus price target of analysts on Wall Street is $5.5, which implies an increase of 216.09% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $7 respectively. As a result, EVFM is trading at a discount of 302.3% off the target high and 72.41% off the low.
Evofem Biosciences, Inc. (EVFM) projections and forecasts
Statistics show that Evofem Biosciences, Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Evofem Biosciences, Inc. (EVFM) shares have jump down -35.79% during the last six months, with a year-to-date growth rate less than the industry average at -26.89% against 8.4%. Yet analysts are winding down their growth forecast for the fiscal year 2021. Revenue is predicted to decline -22.5% this quarter and then jump 57.1% in the quarter after that. In the rating firms’ projections, revenue will increase 5287.9% compared to the previous financial year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 35.4%. While earnings are projected to return -6.5% in 2021, the next five years will return 0% per annum.
Evofem Biosciences, Inc. (NASDAQ:EVFM)’s Biggest Investors
Evofem Biosciences, Inc. insiders own 2.53% of total outstanding shares while institutional holders control 33.98%, with the float percentage being 34.86%. Invesco Ltd. is the largest shareholder of the company, while 128 institutions own stock in it. As of Dec 30, 2020, the company held over 12.7 Million shares (or 15.28% of all shares), a total value of $30.61 Million in shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The next largest institutional holding, with 5.21 Million shares, is of Blackrock Inc.’s that is approximately 6.27% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $12.56 Million.
Also, the Mutual Funds coming in first place with the largest holdings of Evofem Biosciences, Inc. (EVFM) shares are Heartland Value Fund and Vanguard Total Stock Market Index Fund. Data provided on Dec 30, 2020 indicates that Heartland Value Fund owns about 2,000,000 shares. This amounts to just over 2.41 percent of the company’s overall shares, with a $4.82 Million market value. The same data shows that the other fund manager holds slightly less at 1.89 Million, or about 2.28% of the stock, which is worth about $4.56 Million.